Details of the Drug

General Information of Drug (ID: DMA8KQR)

Drug Name

GB0139

Synonyms

TD139; TD-139; 1450824-22-2; olitigaltin; TD 139; GB0139; GB-0139; Olitigaltin [USAN]; 60Y0GUO72B; 3-Deoxy-3-[4-(3-Fluorophenyl)-1h-1,2,3-Triazol-1-Yl]-Beta-D-Galactopyranosyl 3-Deoxy-3-[4-(3-Fluorophenyl)-1h-1,2,3-Triazol-1-Yl]-1-Thio-Beta-D-Galactopyranoside; (2R,2'R,3R,3'R,4S,4'S,5R,5'R,6S,6'S)-6,6'-Thiobis(4-(4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)tetrahydro-2H-pyran-3,5-diol); (2S,3R,4S,5R,6R)-4-[4-(3-Fluorophenyl)triazol-1-yl]-2-[(2S,3R,4S,5R,6R)-4-[4-(3-fluorophenyl)triazol-1-yl]-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]sulfanyl-6-(hydroxymethyl)oxane-3,5-diol; UNII-60Y0GUO72B; TD2; OLITIGALTIN [INN]; Gal-3 Inhibitor GB0139; Galectin-3 Inhibitor GB0139; CHEMBL4297442; SCHEMBL15657269; TD 139 [WHO-DD]; GTPL12148; EX-A1688; BDBM50581762; WHO 12032; AKOS027325618; CS-6265; DB12895; GB 0139; AC-35516; beta-D-Galactopyranoside, 3-deoxy-3-(4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-beta-D-galactopyranosyl 3-deoxy-3-(4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-1-thio-; BS-15429; BT173009; HY-19940; C72753; A857944; Q27263259; bis-(3-deoxy-3-(3-fluorophenyl-1h-1,2,3-triazol-1-yl)-beta-d-galactopyranosyl)-sulfane; .BETA.-D-GALACTOPYRANOSIDE, 3-DEOXY-3-(4-(3-FLUOROPHENYL)-1H-1,2,3-TRIAZOL-1-YL)-.BETA.-D-GALACTOPYRANOSYL 3-DEOXY-3-(4-(3-FLUOROPHENYL)-1H-1,2,3-TRIAZOL-1-YL)-1-THIO-; 3,3'-DIDEOXY-3,3'-BIS-(4-(3-FLUOROPHENYL)-1H-1,2,3-TRIAZOL-1-YL)-1,1'-SULFANEDIYL-DI-.BETA.- D-GALACTOPYRANOSIDE; BIS(3-DEOXY-3-(3-FLUOROPHENYL-1H-1,2,3-TRIAZOL-1-YL)-.BETA.-D-GALACTOPYRANOSYL)SULFANE

Indication

Disease Entry	ICD 11	Status	REF
Idiopathic pulmonary fibrosis	CB03.4	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecule

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C28H30F2N6O8S
Canonical SMILES: C1=CC(=CC(=C1)F)C2=CN(N=N2)C3C(C(OC(C3O)SC4C(C(C(C(O4)CO)O)N5C=C(N=N5)C6=CC(=CC=C6)F)O)CO)O
InChI: InChI=1S/C28H30F2N6O8S/c29-15-5-1-3-13(7-15)17-9-35(33-31-17)21-23(39)19(11-37)43-27(25(21)41)45-28-26(42)22(24(40)20(12-38)44-28)36-10-18(32-34-36)14-4-2-6-16(30)8-14/h1-10,19-28,37-42H,11-12H2/t19-,20-,21+,22+,23+,24+,25-,26-,27+,28+/m1/s1
InChIKey: YGIDGBAHDZEYMT-MQFIMZJJSA-N

Cross-matching ID

PubChem CID: 73774610
TTD ID: DU5G2B

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Galectin-3 (LGALS3)	TTFPQV7	LEG3_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Idiopathic pulmonary fibrosis

ICD Disease Classification

CB03.4

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Galectin-3 (LGALS3)	DTT	LGALS3	4.24E-01	-0.05	-0.08

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

References

1	ClinicalTrials.gov (NCT03832946) GALACTIC-1 -A Randomized, Double-blind, Multicentre, Parallel, Placebo-controlled Phase 2b Study in Subjects With Idiopathic Pulmonary Fibrosis (IPF) Investigating the Efficacy and Safety of GB0139, an Inhaled Galectin-3 Inhibitor Administered Via a Dry Powder Inhaler Over 52 Weeks. U.S.National Institutes of Health.
2	An Inhaled Galectin-3 Inhibitor in COVID-19 Pneumonitis: A Phase Ib/IIa Randomized Controlled Clinical Trial (DEFINE). Am J Respir Crit Care Med. 2023 Jan 15;207(2):138-149.